ISK | R&D | Organic Chemicals Division | Business Operations

HOME > R&D > Organic Chemicals Division > Business Operations > Central Research Institute

Chemical Science Laboratory

Discovery of new agrochemicals including herbicides, insecticides, and fungicides Encouragement of new agrochemical development through support towards gaining approval

Diverse Range Intermediates Laboratory

Research to expand the applications of CF3 pyridine—a core technology of ISK’s Agrochemicals Division
Discovery of new agrochemicals using CF3 pyridine intermediates
Research of new CF3 pyridine intermediates

Process Development Laboratory

Development of manufacturing processes for new agrochemical substances and intermediates
Implementation of basic manufacturing technologies for new agrochemical substances and intermediates
Improvement of manufacturing processes for existing agrochemicals

Bioscience Research Laboratory

Bioactivity assessment of new synthetic compounds
Development and commercialization research of new agrochemicals in the development pipeline
Research to maintain and expand the applications of existing agrochemicals
Commercialization research of in-licensed agents

Formulation Research Laboratory

Research of formulation of new agrochemicals in the development pipeline and basic technologies for manufacturing
Research and development of new formulations of existing agrochemicals

Safety Science Research Laboratory

Initial safety tests relative to metabolism, residues, and toxicology
Support to approval obtention

Research Management Division

Support to patenting and technical research

Life-Science Laboratory

Research and development of medical materials and bio-reagents for diagnostics


	Medical materials for artificial bones
	The application of inorganic materials research to medical technology has been thriving in recent years. Titanium dioxide, one of ISK’s core products, presents a wide range of attractive characteristics. It is classified as an inorganic drug in the Pharmacopeia of Japan and has been used as an encapsulated opacifier. We are working with our Inorganic Chemicals Division on the development of medical materials using existing technologies based on titanium dioxide, which has been shown to be optimal for medical application. We are focusing on one of the characteristics of titanium oxide, in particular its tendency to facilitate in vivo apatite formation for artificial bones.

	“GenomONE” bio-reagent series for HVJ envelope
	In April 2002, we started manufacturing and selling GenomONE—a transfection kit for gene function analysis which was followed by GenomONE-Neo. GenomONE is the fruit of an industry–academia joint development program with Osaka University, Japan, and its bio venture. In February 2006, we also launched the GenomONE-CF cell fusion kit and, in October 2007, the GenomONE-CAb transfection kit for specific antibody delivery. In the Life-Science Laboratory, we have been working on the research and development of the GenomONE series to enhance vector function performance. We are focusing on adding an in vivo drug delivery system and, in addition to genes, achieving high efficiency transfection for proteins and other substances. We are also exploring the creation of new antibodies by synthesizing GenomONE-CF-based hybridomas. Furthermore, we have been involved in industry-government-academia joint research to develop new diagnostic agents.